title: Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation by peptidomimetic opioid compound.
abstract: In continuation to our earlier studies with peptidomimetic opioid compounds, we have further investigated immunosuppressive properties of one of our peptidomimetic compound (Tyr-NH-CH2-CH2-O-Phe-NH2) using peripheral blood mononuclear cells (PBMCs) of healthy volunteers. Peptidomimetic compound was evaluated for its effect on anti-CD3 and recombinant human interleukin-2 (rhIL-2) stimulated lymphocyte proliferation in vitro and lipopolysaccharide (LPS) induced activation of mitogen activated protein kinase (MAPK, pp42/44) in mouse macrophage cells (RAW 264.7). Our results show the immunosuppressive potential of synthetic peptidomimetic compound. This compound significantly inhibited anti-CD3 and rhIL-2 stimulated lymphocyte proliferation in vitro. However, this peptidomimetic compound did not show any effect on LPS induced MAPK activation. These observations suggest that above peptidomimetic compound has potential to inhibit immune responses mediated by lymphocytes.
authors.affiliation: Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India.
authors.forename: P
authors.initials: P
authors.lastname: Narayan
authors.forename: R
authors.initials: R
authors.lastname: Pandey
authors.forename: V S
authors.initials: VS
authors.lastname: Yadav
authors.forename: R
authors.initials: R
authors.lastname: Tandon
authors.forename: W
authors.initials: W
authors.lastname: Haq
authors.forename: M M
authors.initials: MM
authors.lastname: Dhar
authors.forename: V K
authors.initials: VK
authors.lastname: Singh
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D004789:Enzyme Activation; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D018847:Opioid Peptides / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D018847:Opioid Peptides; D011994:Recombinant Proteins; D020929:Mitogen-Activated Protein Kinase Kinases